Global Information

Recruitment – complete
Total Patients Enrolled – 57,262

  • 5,080 Retrospective
  • Cohort 1 – 5,505
  • Cohort 2 – 11,681
  • Cohort 3 – 11,485
  • Cohort 4 – 11,310
  • Cohort 5 – 12,201

View global reports here


Thromboembolic stroke represents a major challenge and its prevention will be a defining component of population healthcare in the 21st century.

This worldwide observational programme aims to enhance the breadth and depth of understanding of stroke prevention in atrial fibrillation (AF), ultimately informing strategies to improve patient outcomes, safety and utilisation of healthcare resources.

GARFIELD-AF offers a unique opportunity to obtain a comprehensive and contemporary description of the spectrum of patients with AF and their management worldwide as they evolve over time.

GARFIELD-AF is important in bridging the gap between research and clinical practice, serving to increase awareness of the importance of thrombosis and its treatment.

Travel Through Our Timeline

Scroll over the window below to view our timeline

  • 2009
  • First Patient
  • 2010
  • 2011
  • First data presented Baseline data describing global treatment patterns
  • Cohort 1 Complete 10,618 patient describing the end of the VKA only era
  • Methods Paper published
  • 2012
  • Preliminary Follow-up Data
    First description of outcomes according to treatment
  • 2013
  • Cohort 1 Baseline Paper published
  • Cohort 2 Complete
    11,787 prospective patients recruited in 35 countries Cohort 3 Starts
  • 2014
  • Cohort 3 Complete
    33,751 patients recruited in 35 countries
  • Cohort 4 Starts
  • 2015
  • Gender Baseline Paper published
  • Cohort 4 Complete and Start of Cohort 5 45,050 patients recruited in 35 countries
  • 2016
  • Cohort 5 57,262 patients enrollled; recruitment completed

Study Design

GARFIELD-AF is recruiting patients with newly diagnosed nonvalvular AF and at least one risk factor for stroke.

Patients have been recruited over five sequential cohorts.
Follow-up is over a minimum of 2 years and up to 8 years after diagnosis, to create a comprehensive database of treatment decisions and outcomes in everyday clinical practice.

Challenges associated with observational studies and design features of GARFIELD-AF

ChallengesDesign features of GARFIELD-AF registry
Capturing the whole burden of diseaseProspective recruitment of patients with long-term follow-up
  • Enrolment of 57,262 patients from over 1000 centres in 35 countries worldwide, including the Americas, Europe, Africa and Asia-Pacific
Ensuring high quality dataComprehensive programme of audit and quality control
  • 20% source data verification under the supervision of an independent audit committee
Describing everyday clinical practiceNon-interventional study design
  • Random selection of sites that are representative of the national care setting
Enrolling a representative sample of patientsUnrestricted inclusion criteria
  • Enrolment of patients without exclusion according to comorbidities or treatment

Patient Eligibility

Patient eligibility

  • Age 18 years and over
  • New diagnosis of non-valvular atrial fibrillation (diagnosed within the last 6 weeks) with at least one investigator-determined risk factor for stroke

End Points

Over a period of 8 years (between December 2009 and August 2018), GARFIELD-AF will:

  • Describe changes in treatment practice
  • Quantify rates of stroke and systemic embolism, major bleeding and all-cause mortality
  • Assess therapy persistence (including discontinuation, interruption, and changes of regimen) and fluctuations in the international normalised ratio for patients on vitamin K antagonists

Quality Assurance

GARFIELD-AF is governed by the highest academic and ethical standards in the generation, dissemination, and communication of its research findings

Audit requirements

  • 20% of all electronic case report forms are monitored against source documentation
  • Electronic audit trail for all data modifications
  • Critical variables are subjected to additional audit
  • Compliant with Declaration of Helsinki

Global status

Read more
Total patients 57,262
Recruitment Recruitment closed
Study end: 2018

Members Login

Coming soon… If you would like to be notified of when this is available click here and add your details to receive updates

Newsletter Signup

    Please see our Privacy Policy and Cookie Policy

    Contact Us

      To find out more about GARFIELD-AF, please contact the Thrombosis Research Institute

      E: garfield@tri-london.ac.uk
      T: 0203 198 9947